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Causes of death in pediatric 
systemic lupus erythematosus
Sirs,
Pediatric systemic lupus erythematosus 
(pSLE) remains a severe disease although 
its prognosis has improved with time. Use 
of new therapies may result in modifying 
the causes of mortality. Death was mostly 
due to renal insufﬁciency and infections 
(1-4) during the 1980-1990 decade, while 
no death was recorded in the sole study 
enrolling children strictly after 1990 (5). 
The purpose of this study is to document 
the changes in causes of mortality in pSLE 
over the past 10 years in order to better pre-
vent them.
This French retrospective multicenter study 
included all pSLE patients followed in 
pediatric centers who died before the age 
18 years during the 1996-2006 decade. All 
of them fulﬁlled the American College of 
Rheumatology (ACR) classiﬁcation cri-
teria for SLE, and were diagnosed before 
16 years of age. A questionnaire was sent 
to the 44 pediatric nephrology and rheu-
matology units of French university hospi-
tals. The authors classiﬁed retrospectively 
the cause of death as organ involvement 
resulting from active uncontrollable SLE, 
thrombosis, therapy-related or infection-
related event; the predominant cause was 
considered when there was some possible 
overlapping causes of mortality. 
Thirty-nine of the 44 (88%) centers re-
sponded to our questionnaire and recorded 
death in 12 patients, whom main demo-
graphic and clinical features are summa-
rized in Table I. Death resulted from SLE 
organ involvement, including three cases 
of pancreatitis, thrombosis, infection in 5, 
4 and 3 patients respectively. A therapy-re-
lated event was assessed in one patient who 
died during a conditioning regimen before 
autologous bone marrow transplantation 
(ABMT), and was suspected in another 
who had cerebral histoplasmosis, 5 months 
after being treated sequentially with rituxi-
mab (RTX) and cyclophosphamide (Table 
I). His serum immunoglobulin G level (400 
mg/dL) and lymphocyte count (1.1 x 109/L) 
were low at time of death. The twelfth pa-
tient committed suicide.
The present series emphasizes that pSLE 
remains a potentially fatal disease during 
the pediatric age. Unfortunately, the retro-
spective design of this multicenter study 
did not allow us to determine the mortal-
ity rates. Deaths were due to SLE exacer-
bation, thromboses, infections, but also 
to new therapies related events. The most 
signiﬁcant change in survival over time oc-
curred in patients with renal involvement. 
Renal failure, responsible for most of the 
deaths before 1990 (1-5), was not a cause 
of mortality anymore. Conversely, within 
the last decade, new therapies proposed to 
SLE patients, including RTX and ABMT, 
result in new toxicities. Tolerance of RTX 
is generally good in the treatment of au-
toimmune diseases. However, one out of 48 
patients reported in the three pSLE studies 
(6-8) died from severe sepsis after sequen-
tial treatment with intravenous cyclophos-
phamide and RTX (6), as did one patient of 
the present series. Although the relationship 
to RTX therapy was unclear in these two 
patients, these features highlight that the 
safety of rituximab remains to be clariﬁed. 
ABMT resulted in death in one patient ; 
now, it must have almost no indication in 
the treatment of  pSLE. Acute pancreatitis 
was responsible for death in three patients, 
including a fulminating pancreatitis re-
vealing SLE in our series. Thus, it should 
be promptly treated with corticoidsteroid 
treatment after infectious disease and side 
effects of treatment have been excluded. 
(9). It also highlights the need for pneumo-
coccal immunization in SLE patients since 
one patient died from pneumococcal sepsis. 
Thrombosis led to death in 2/4 patients who 
had antiphospholipid (aPL) antibodies, co-
existing with other risk factors for throm-
bosis, including a prolonged air travel and 
a pneumoccocal sepsis respectively in the 
Table I. Clinical and demographic details of the 12 pSLE  patients  included in the study.
Patient Age at death Time elapsed Organ involvement before the event aPL positivity Previous therapies Cause of death   
 (y)/ from death which led to death
 Sex / Ethnicity (months)    
  
1 16/F/FOC 81 Arthritis, pericarditis, myocarditis*  No Pred*, MP**, CYC**, plasmapheresis** SLE pancreatitis
   nephritis (class IV)* , pancreatitis, 
   hemophagocytic syndrome*  
 
2 11/F/Ca 0.6 Rash* , pancreatitis, thrombocytopenia*  No Pred*, MP** SLE pancreatitis
 
3 11/M/FOC 6 Rash, pancreatitis Yes Pred* Pulmonary thromboembolism  
      during a long-distance air travel
 
4 15/F/Af 36 Arthritis, pericarditis, thrombocytopenia, No AZA, Pred*,  MP*, CYC* ,  MMF  Myocardial infarction during 
   nephritis (class IV)*     conditioning regimen for ABMT
 
5 5/F/Af 8 Rash, arthritis, endocarditis, pancreatitis No Pred, AZA, CYC, MMF*, RTX*,  SLE pancreatitis, 
   nephritis (class IV)  MP**, plasmapheresis** microangiopathic vasculopathy
 
6 9/M/As 36 Neurolupus* , rash* , hepatitis* ,  No Pred*,  MP**, antimalarials , CYC* SLE encephalitis
   pancreatitis, nephritis (class I),   (status epilepticus) 
   thrombocytopenia*    
 
7 9/F/Ca 73 Nephritis (class V), arthritis* , rash No Pred*, MMF*, RTX*, AZA, MTX,  Pulmonary haemorrhage
 
8 16/F/Ca 0.2 Nephritis (class IV)* , lupus vasculitis No Pred*, MP*, CYC*, heparin**  Pulmonary thromboembolism
   neurolupus* ,pancreatitis   (uncontrolled nephrotic 
      syndrome)
 
9 9/F/Ma 0.4 Nephritis* , thrombocytopenia* ,  Yes Pred*, MP*, heparin** Pneumococcal sepsis
   haemolytic anemia* , arthritis*    Catastrophic antiphospholipid  
      syndrome
 
10 14/F/Ca 34 Rash No Antimalarials* Suicide
 
11 13/F/FOC 42 Nephritis (class IV), rash, pericarditis,  Yes Pred*,CYC*, MTX, MMF, RTX , MP**, Histoplasmosis encephalitis
   enteritis, seizure*    plasmapheresis**  
 
12 15/F/FOC 8 Rash, arthritis* , pancreatitis, lupus neurolupus*  Yes AZA, Pred*, antimalarials  Streptococcal A sepsis
C: Caucasian; Af: African; As: Asian; FOC: French oversea collectivities; CYC: cyclophosphamide; MTX:  methotrexate; MMF: mycophenolate mofetil; AZA: azathioprine; 
RTX: Rituximab; Pred: prednisone; MP: methylprednisolone shots; aPL: antiphospholipid; ABMT: autologous bone marrow transplantation.
* indicates the treatment and involvements already present when the event which led to death occurred.
* * indicates the treatment of the event which led to death.
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present series. The recent EULAR expert 
committee recommendation of using low 
dose aspirin in SLE patients with aPL an-
tibodies, especially when other risk fac-
tors for thrombosis coexist (10), must be 
prospectively evaluated.  Deaths still occur 
during the pediatric age in pSLE patients. 
Prompt management of SLE pancreatitis 
and antipneumococcal immunization are 
warranted in the management of pSLE pa-
tients, and ongoing vigilance is needed af-
ter treatment with rituximab.
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